🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA approves zanubrutinib for CLL/SLL any line of therapy! #lymsm fda.gov/drugs/resource…

We brought the A-team to USCLC! Winship Cancer Institute of Emory University #CTCL Mary Jo Lechowicz Katherine Case

Important PSA. Dupilumab does not work in CTCL! Great work by Dr. Alkilov’s team presented USCLC #CTCL Winship Cancer Institute of Emory University

Nivo-AVD > BV-AVD in advanced stage classical Hodgkin Lymphoma!? "With a median follow-up of 12.1 months, the PFS was superior in the N-AVD arm [HR 0.48, 99% CI 0.27-0.87, one-sided p=0.0005); 1-year PFS was 94% after N-AVD compared to 86% after BV-AVD." Ohio State Hematology #lymsm

Amazing!!! I remember when I was told frontline PD-1 was a crazy concept… fast forward to our ASH presentation of frontline pembro showing perfect outcomes and being told there was not enough interest generated from my presentation to move forward! Merck missed out!

Great morning session at Highlights of ASH- Latin America in São Paulo, Brazil. Learning about Severe Aplastic Anemia, hemophilia, and Car-T #HOALA2023 ASH

That’s a wrap to Highlights of ASH, Latin America! My first time co-chairing! Thanks to my co-chairs ⁦Amy DeZern⁩ for guidance! #HOALA2023 ⁦ASH⁩

Such a great event Winship Cancer Institute of Emory University Marlise R. Luskin MD, MSCE #HOALA2023

@austinlouisray.bsky.social @katiehawk If we can get Decaturish up to 10,000 subscribers, we'll give ATL one of the best digital news websites in the country. We already know who we would hire and why. There are tons of great journalists around here waiting for a chance. We just lack a sustainable revenue stream.

Agree. Dana-Farber Dr LaCasce Ann LaCasce, MD did a marvelous job (w/ beautiful graphics) setting the stage and putting this plenary talk in perfect context. And City of Hope Dr Herrera then knocked it out of the park. 🏟️ Big kudos all the way around! 👏👏 #ASCO2023 #ASCO23 #lymsm

Important article by @RaphaelESteiner showing reducing the dose of brentuximab in A+ AVD in practice does not seem to impact outcomes. Important when counseling our patients who want to keep on high doses, despite neuropathy!

Let's make sure every voter can cast their ballot in the upcoming election! I just ordered a free, nonpartisan voter badge from Vot-ER so I can offer patients the opportunity to register to vote or view their ballot right in the clinic. Get yours ⤵️ get.vot-er.org/badge

So proud of you!! I remeber your first oral presentation at USCLC!

As a T-cell lymphoma specialist, I can tell you this is exceedingly rare. In an email sent in response to this announcement to T-cell docs at ~ 20 of the largest centers, none of us have seen this. Matt Lunning D.O. Barbara Pro Jaehyuk Choi

GREAT work from one of our small group mentees, Ronak H. Mistry, DO! Shout out to the amazing work being done in medical education through the ASH Medical Educator Institute! #ASHMEI ASH Srikanth Nagalla, MD

Agreed! For all advanced stage but especially elderly with significant improvement in tolerability and response…. Now what to do with early stage.

#NewProfilePic

Meanwhile adult oncology, very high professional fulfillment, but also one of the worst for burnout… sounds about right.

Oral JAK-1 inhibitor Golidocitinib in r/r PTCL. JACKPOT8 Part B. 44% ORR, with median DOR 20 mo. ~ 60% PTCL, NOS. 94% patients were Asian, very few treated in US. Early promising data, but will need to be confirmed in a US based study. sciencedirect.com/science/articl…